Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel DiseaseJeffrey S. Hyams, Meena Thayu, Anne M. Griffiths et al.|Gastroenterology|2017Cited by 217
Surgical Management of Crohn Disease in ChildrenJorge Amil Dias, Sanja Kolaček, Dan Turner et al.|Journal of Pediatric Gastroenterology and Nutrition|2017Cited by 100
41 Serious Infections and Associated Risk Factors in Patients Receiving Infliximab and Immunotherapies for Children With Inflammatory Bowel Disease: Develop Registry DataRobert N. Baldassano, Harland S. Winter, Richard B. Colletti et al.|Gastroenterology|2013Cited by 8
833 Malignancies in Children Receiving Infliximab and Other Inflammatory Bowel Disease Therapies: An Inflammatory Bowel Disease Multicenter, Prospective, Long-Term Registry of Pediatric Patients (Develop) Registry DataRichard B. Colletti, Gigi Veereman, Salvatore Cucchiara et al.|Gastroenterology|2013Cited by 7
629 Risk of Malignancy in Pediatric Inflammatory Bowel Disease: Results From the DEVELOP RegistryJeffrey S. Hyams, Meena Thayu, Marla Dubinsky et al.|Gastroenterology|2016Cited by 2